Manages OA 1.2 Rheumatoid Arthritis (RA). ANDA 208856, held by Qingdao Baheal Pharm. Celecoxib.
As of Nov 15, 2026, ANDA 208856 (Celecoxib), held by Qingdao Baheal Pharm, was first approved by FDA on Aug 7, 2019, with 1 approved supplement and 0 published complete response letters.
Celecoxib capsules are indicated Celecoxib is a nonsteroidal anti-inflammatory drug indicated for: Osteoarthritis (OA) Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis (JRA) in patients 2 years and older Ankylosing Spondylitis (AS) Acute Pain (AP) Primary Dysmenorrhea (PD) 1.1 Osteoarthritis (OA) For the management of the signs and symptoms of OA 1.2 Rheumatoid Arthritis (RA) For the management of the signs and symptoms of RA 1.3 Juvenile Rheumatoid Arthritis (JRA) For the management of the signs and symptoms of JRA in patients 2 years and older 1.4 Ankylosing Spondylitis (AS) For the management of the signs and symptoms of AS 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 7, 2019 | Original application | Approved | None posted |
| Feb 12, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 7, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters